Core Scientific (CORZ) Current Deferred Revenue (2021 - 2026)

Core Scientific (CORZ) has 6 years of Current Deferred Revenue data on file, last reported at $654.2 million in Q1 2026.

• Quarterly Current Deferred Revenue rose 974.26% year-over-year to $654.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $654.2 million (up 974.26% YoY) and the FY2025 annual result came in at $555.9 million, up 2965.24% from the prior year.
• Current Deferred Revenue rose to $654.2 million in Q1 2026 per CORZ's latest filing, from $555.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $654.2 million in Q1 2026, with the low at $2.5 million in Q3 2025.
• Average Current Deferred Revenue over 5 years is $142.5 million, with a median of $69.3 million recorded in 2022.
• Year-over-year, Current Deferred Revenue slumped 87.35% in 2023 and surged 2965.24% in 2025.
• Core Scientific's Current Deferred Revenue stood at $77.7 million in 2022, then tumbled by 87.35% to $9.8 million in 2023, then surged by 84.48% to $18.1 million in 2024, then surged by 2965.24% to $555.9 million in 2025, then climbed by 17.7% to $654.2 million in 2026.
• Business Quant data shows CORZ's Current Deferred Revenue at $654.2 million in Q1 2026, $555.9 million in Q4 2025, and $2.5 million in Q3 2025.